Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.
Alcohol use disorders (AUDs)
HIV
Naltrexone
Systematic review
Treatment
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
18 03 2020
18 03 2020
Historique:
received:
21
12
2019
accepted:
10
03
2020
entrez:
20
3
2020
pubmed:
20
3
2020
medline:
27
2
2021
Statut:
epublish
Résumé
Because alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary. This systematic review contains studies that examine the effects of pharmacological intervention (oral naltrexone (NTX) or injectable extended-release naltrexone (XR-NTX)) on the persons living with HIV and AUDs. A systematic literature search using three electronic databases including Pubmed Medline, Scopus and the Cochrane Library and Google Scholar was conducted and includes articles published from 1995 to 2019. Records were collected by searching relevant keywords and those that meet the inclusion/exclusion criteria are included. Overall, in this systematic review, the results of 7 relevant studies including pilot and randomized controlled/clinical trials were summarized and reviewed. Among selected records 2 of these assessed the efficacy of NTX and 5 tested the XR-NTX effectiveness in treating AUDs among persons living with HIV (PLH). In summary, with some expectations, NTX and XR-NTX administration in persons living with HIV and AUDs led to reduced alcohol use, improved viral suppression, unchanged ART adherence and has no significant adverse events. The findings of this systematic review suggest the beneficial effects and safety of the NTX and XR-NTX for treating AUDs in PLH. Further studies are needed in the future to focus on the treatment of AUDs in people living with HIV.
Sections du résumé
BACKGROUND
Because alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary.
OBJECTIVES
This systematic review contains studies that examine the effects of pharmacological intervention (oral naltrexone (NTX) or injectable extended-release naltrexone (XR-NTX)) on the persons living with HIV and AUDs.
METHODS
A systematic literature search using three electronic databases including Pubmed Medline, Scopus and the Cochrane Library and Google Scholar was conducted and includes articles published from 1995 to 2019. Records were collected by searching relevant keywords and those that meet the inclusion/exclusion criteria are included.
RESULTS
Overall, in this systematic review, the results of 7 relevant studies including pilot and randomized controlled/clinical trials were summarized and reviewed. Among selected records 2 of these assessed the efficacy of NTX and 5 tested the XR-NTX effectiveness in treating AUDs among persons living with HIV (PLH). In summary, with some expectations, NTX and XR-NTX administration in persons living with HIV and AUDs led to reduced alcohol use, improved viral suppression, unchanged ART adherence and has no significant adverse events.
CONCLUSION
The findings of this systematic review suggest the beneficial effects and safety of the NTX and XR-NTX for treating AUDs in PLH. Further studies are needed in the future to focus on the treatment of AUDs in people living with HIV.
Identifiants
pubmed: 32188486
doi: 10.1186/s13011-020-00266-6
pii: 10.1186/s13011-020-00266-6
pmc: PMC7081595
doi:
Substances chimiques
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
Alcohol Alcohol. 2016 Sep;51(5):562-6
pubmed: 27402770
Gastroenterology. 2011 Nov;141(5):1572-85
pubmed: 21920463
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):92-100
pubmed: 29781884
BMJ. 2015 Aug 18;351:h4238
pubmed: 26286216
CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22
pubmed: 20201811
J Gen Intern Med. 1995 Aug;10(8):458-60
pubmed: 7472704
Curr Opin Infect Dis. 2018 Feb;31(1):1-7
pubmed: 29176446
AIDS Behav. 2019 Jan;23(1):211-221
pubmed: 30073637
Am J Drug Alcohol Abuse. 2015;41(6):479-88
pubmed: 26286352
Contemp Clin Trials. 2017 Sep;60:72-77
pubmed: 28642209
J Control Release. 2014 Jun 10;183:154-66
pubmed: 24704710
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
pubmed: 1345133
JAMA. 2014 May 14;311(18):1889-900
pubmed: 24825644
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
J Clin Psychiatry. 2008 Feb;69(2):190-5
pubmed: 18348601
Antimicrob Agents Chemother. 2000 Jun;44(6):1686-90
pubmed: 10817729
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Alcohol Clin Exp Res. 2011 Dec;35(12):2121-7
pubmed: 21682753
Addiction. 2003 Jul;98(7):901-11
pubmed: 12814496
Addiction. 2006 Jun;101(6):824-34
pubmed: 16696626
JAMA. 2006 May 3;295(17):2003-17
pubmed: 16670409
Alcohol Clin Exp Res. 2016 Oct;40(10):2056-2072
pubmed: 27696523
Subst Abus. 2017 Jul-Sep;38(3):269-277
pubmed: 27925867
J Psychopharmacol. 2012 Jul;26(7):899-952
pubmed: 22628390
AIDS Behav. 2019 Jan;23(1):140-151
pubmed: 29995206
J Subst Abuse Treat. 2018 Feb;85:105-108
pubmed: 29174308
J Infect Dis. 1996 Mar;173(3):550-8
pubmed: 8627016
Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94
pubmed: 10470982
BMC Infect Dis. 2017 Apr 11;17(1):263
pubmed: 28399823
AIDS Res Hum Retroviruses. 2004 Feb;20(2):151-5
pubmed: 15018702
Infection. 2009 Aug;37(4):334-9
pubmed: 19629382
J Stud Alcohol. 2002 Mar;63(2):179-86
pubmed: 12033694
AIDS. 2016 Jan;30(2):273-91
pubmed: 26691548
Br J Nutr. 2007 Oct;98 Suppl 1:S111-5
pubmed: 17922947
Hepatology. 1999 Oct;30(4):1054-8
pubmed: 10498659
Ann Intern Med. 2006 May 16;144(10):705-14
pubmed: 16702586
Eur Addict Res. 2017;23(4):204-210
pubmed: 28877518
J Subst Abuse Treat. 2009 Jan;36(1):1-6
pubmed: 18775624
AAPS J. 2005 Oct 27;7(3):E704-22
pubmed: 16353947
Open Forum Infect Dis. 2015 Jan 20;2(1):ofu120
pubmed: 26034751
Alcohol Alcohol. 1999 Nov-Dec;34(6):830-41
pubmed: 10659718
Addiction. 2017 Jun;112(6):1036-1044
pubmed: 28061017
JAMA. 2005 Apr 6;293(13):1617-25
pubmed: 15811981
Int J STD AIDS. 1999 Sep;10(9):561-70
pubmed: 10492422
Curr HIV/AIDS Rep. 2015 Dec;12(4):421-36
pubmed: 26412084
Am J Prev Med. 2016 Aug;51(2):206-215
pubmed: 27178884
J Stud Alcohol Suppl. 2005 Jul;(15):170-8; discussion 168-9
pubmed: 16223068
Drug Alcohol Depend. 2017 May 1;174:158-170
pubmed: 28334661